Mereo BioPharma is facing a securities class action that names CEO Denise Scots-Knight and CSO John Lewicki as individual defendants under Section 20(a) control-person claims. The complaint alleges the executives had authority over the company’s public statements and participated in investor communications that contained materially misleading statements about the setrusumab program. It also alleges they had access to non-public information that contradicted their public statements. Investors seeking to be considered for lead plaintiff must file by April 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603110900PR_NEWS_USPR_____NY07399) on March 11, 2026, and is solely responsible for the information contained therein.